title: Beneficial effects of HLA class II incompatibility in living donor liver transplantation.
abstract: OBJECTIVE
  To analyze the impact of HLA matching in both patient and graft evolution after LDLT.
  
  
  METHODS
  Twenty recipients underwent LDLT with follow-up of 3 to 30 months. HLA typing was performed on all donor-recipient pairs; class I antigens were typed using serological methods and class II loci (DRB1 and DQB1) using low-resolution molecular typing. Recipient sera were cross-matched with donor lymphocytes. Antigen mismatches were analyzed for each locus individually, for each class as a whole and for HLA class I immunogenic triplets according to HLA Matchmaker software.
  
  
  RESULTS
  Eighteen of 20 donor-recipient pairs were HLA haploidentical. All but one of the recipients had a negative cross-match before transplantation. While there was not a statistically significant correlation between HLA class I mismatches and the incidence of acute rejection episodes, HLA class II matching in DRB1 and DQB1 loci appeared to be associated with a higher incidence of acute rejection episodes after LDLT. Both host-versus-graft (HvG) and graft-versus-host (GvH) HLA class II compatibilities correlated with rejection episodes, especially for the GvH direction.
  
  
  CONCLUSIONS
  HLA class II matching for DRB1 and DQB1 loci appears to be associated with a higher incidence of acute rejection episodes after LDLT. In this study, mismatches in class I HLA antigens are not related to an higher incidence of acute rejection episodes nor other complications after LDLT. Further studies are needed to unveil the role of HLA matching in LDLT.
authors.affiliation: Immunology Department, Hospital Ramón y Cajal, Madrid, Spain. jcampos.hrc@salud.madrid.org
authors.forename: J
authors.initials: J
authors.lastname: Campos
authors.forename: Y
authors.initials: Y
authors.lastname: Quijano
authors.forename: A
authors.initials: A
authors.lastname: Franco
authors.forename: P
authors.initials: P
authors.lastname: Eiras
authors.forename: M
authors.initials: M
authors.lastname: López-Santamaria
authors.forename: M
authors.initials: M
authors.lastname: Gámez
authors.forename: J
authors.initials: J
authors.lastname: Núño
authors.forename: J
authors.initials: J
authors.lastname: Murcia
authors.forename: P
authors.initials: P
authors.lastname: López
authors.forename: G
authors.initials: G
authors.lastname: Zarzosa
authors.forename: M
authors.initials: M
authors.lastname: Garcia
authors.forename: A
authors.initials: A
authors.lastname: Albillo
authors.forename: R
authors.initials: R
authors.lastname: Bárcena
authors.forename: J L
authors.initials: JL
authors.lastname: Castañer
authors.forename: E
authors.initials: E
authors.lastname: Vicente
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006683:HLA-DQ Antigens / Q000032:analysis; D059866:HLA-DQ beta-Chains; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D016031:Liver Transplantation / Q000276:immunology*; D019520:Living Donors; D008297:Male; D009679:Nuclear Family
chemical_list: D006683:HLA-DQ Antigens; D059866:HLA-DQ beta-Chains; C069051:HLA-DQB1 antigen; D000949:Histocompatibility Antigens Class II